Core Fucosylation Mediated by the FucT-8 Enzyme Affects TRAIL-Induced Apoptosis and Sensitivity to Chemotherapy in Human SW480 and SW620 Colorectal Cancer Cells

Int J Mol Sci. 2023 Jul 25;24(15):11879. doi: 10.3390/ijms241511879.

Abstract

Epithelial cells can undergo apoptosis by manipulating the balance between pro-survival and apoptotic signals. In this work, we show that TRAIL-induced apoptosis can be differentially regulated by the expression of α(1,6)fucosyltransferase (FucT-8), the only enzyme in mammals that transfers the α(1,6)fucose residue to the pentasaccharide core of complex N-glycans. Specifically, in the cellular model of colorectal cancer (CRC) progression formed using the human syngeneic lines SW480 and SW620, knockdown of the FucT-8-encoding FUT8 gene significantly enhanced TRAIL-induced apoptosis in SW480 cells. However, FUT8 repression did not affect SW620 cells, which suggests that core fucosylation differentiates TRAIL-sensitive premetastatic SW480 cells from TRAIL-resistant metastatic SW620 cells. In this regard, we provide evidence that phosphorylation of ERK1/2 kinases can dynamically regulate TRAIL-dependent apoptosis and that core fucosylation can control the ERK/MAPK pro-survival pathway in which SW480 and SW620 cells participate. Moreover, the depletion of core fucosylation sensitises primary tumour SW480 cells to the combination of TRAIL and low doses of 5-FU, oxaliplatin, irinotecan, or mitomycin C. In contrast, a combination of TRAIL and oxaliplatin, irinotecan, or bevacizumab reinforces resistance of FUT8-knockdown metastatic SW620 cells to apoptosis. Consequently, FucT-8 could be a plausible target for increasing apoptosis and drug response in early CRC.

Keywords: DR4; FUT8 knockdown; TRAIL-induced apoptosis; colorectal cancer; core fucosylation.

MeSH terms

  • Animals
  • Apoptosis / genetics
  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Fucosyltransferases* / genetics
  • Fucosyltransferases* / metabolism
  • Humans
  • Irinotecan
  • Mammals / metabolism
  • Oxaliplatin

Substances

  • Fucosyltransferases
  • Irinotecan
  • Oxaliplatin

Grants and funding

R.L.-C. acknowledges the AP-FPU12/03662 doctoral grant awarded by the Ministerio de Educación y Ciencia, Spain. A.F.-B. and E.G.-M. appreciate the financial support provided within the framework of the projects “Contrato-Programa de Consolidación de Unidades de Investigación Competitivas CN 2011/024” and “Contrato-Programa de Consolidación de Grupos de Referencia Competitiva GRC 2014/019” (Xunta de Galicia, Spain).